Overview

• TDN is derived from octadecaneuropeptide (ODN), a peptide produced by brain glia that influences neural regulation of hunger.
• In mice, TDN enhanced blood sugar control; in rats and shrews it drove weight loss without causing nausea or vomiting.
• Treated animals exhibited no adverse changes in heart rate, activity levels or body temperature during preclinical trials.
• Blocking ODN signaling in rats weakened the effects of GLP-1 drugs, highlighting ODN’s role in appetite suppression.
• Researchers say they could begin human clinical trials of ODN-based therapies within two years if further safety and efficacy studies prove successful.